Dermatology Drugs Market - High Prevalence and Increase in Incidence of Chronic & Infectious Dermatological Disorders to Boost Market

New York City, 04 March 2019: Polaris Market Research assumes that with the expected launch of the potential promising therapies, the market is anticipated to expand in both psoriasis and atopic dermatitis segments. The Unites States accounts for the higher share of the market as compared to the Europe and Japan. The highest market size is due to the increased adoption of high priced biologics. Despite the launch and availability of multiple biologics, only 10% of the patients have access to these treatments and the market continues to remain underpenetrated.

Currently, the Dermatology Drugs Market is highly fragmented but offer several commercial opportunities. There remains significant unmet need for safer and cost-effective treatment options. Psoriasis market was nearly USD 6 billion markets in 2016 due to the existing effective TNF alpha treatments. In Acne, retinoids and antibiotics are the mainstay treatments but what makes this indication lucrative is the promising candidates in the pipeline including Foamix’s FMX-101 and Dermira’s DRM-101.

Polaris Market Research has provided the forecasts of the Global Dermatology Drugs Market from 2016-2022. The major segments which has been investigated in the global market from 2016-2022 are:

• Market Analysis by Dermatology Key Indications
• Market Analysis by Treatment Class/Marketed Drugs
• Market Analysis by Regions

The Marketed Therapies undertaken in forecast from 2016-2022 are:

• etanercept; Enbrel
• infliximab; Remicade
• adalimumab; Humira
• ustekinumab; Stelara
• secukinumab; Cosentyx
• ixekizumab; Taltz
• golimumab; Simponi
• brodalumab; Siliq
• guselkamab; Tremfya
• Topical Drugs
• Oral Antibiotics

Request For Sample

The Major Indications in Dermatology Therapy area:

• Atopic Dermatitis
• Psoriasis
• Acne
• Rosacea

Leading Companies investigated in the Report are:

• Allergan Plc
• Valeant Pharmaceuticals
• Dermira Inc
• Aclaris Therapeutics, Inc
• AnaptysBio, Inc
• Revance Therapeutics
• Foamix Pharmaceuticals
• Novan, Inc
• Sienna Biopharmaceuticals
• Pfizer
• Sanofi
• Galderma
• Leo Pharma
• Roviant Sciences
• Otsuka Pharmaceuticals

Read More: https://www.polarismarketresearch.com/industry-analysis/dermatology-drugs-market

Pharmaceutical Robots Market Rise in Awareness about Robotic Machines to Boost the Market Growth

New York City, 04 February 2019: The global Pharmaceutical Robots Market is anticipated to reach USD 452.7 Million by 2025 according to a new report published by Polaris Market Research. In 2017, on the basis of application type, inspection of pharmaceutical drugs segment holds the largest market share in this market. Regionally, North America accounted for the major share in the global Pharmaceutical Robots Market.

Growth in global Pharmaceutical Robots Market is primarily driven by the expanding pharmaceutical industry, and rising need for automation in this industry. Also, increasing acceptance of laboratory automation robot and benefits associated with enabling reduction in human interventions and errors is expected to boost the pharmaceutical robot adoption. Additionally, growing demand for drug manufacturing, and increasing technological advancements in the robotic machines positively influence growth in Pharmaceutical Robots Market. Similarly, the adoption of pharmaceutical robots facilitates cost reduction in human labor, that directly led to minimization of production cost.

Request For Sample

On the basis of product type, the global Pharmaceutical Robots Market is segmented into traditional robot, and collaborative robot. Traditional robot is observed to be the dominating segment in terms of market share. However, collaborative robot segment is anticipated to grow at a faster rate, owing to its ease of maintenance compared to the traditional ones.

The traditional Robot are further sub-segmented into articulated robot, SCARA robot, delta/parallel robot, cartesian robot, and dual-arm robot. Articulated robot is popular in market due to their ability to inspect the packing of pharmaceutical products. On the other hand, SCARA robot are expected to showcase a positive growth over the forecast period, due to lower cost of associated machines in comparison of other robot categories

Based on the application type, the global Pharmaceutical Robots Market is sub segmented into picking and packaging, laboratory applications, and inspection of pharmaceutical drugs. Inspection of pharmaceutical drugs segment to hold the domination position during the forecast period. Growth in this segment is majorly observed due to rise in government interventions and stringent policies for approving any type of drug entry in the market. These inspection robots are majorly used for detecting cracks on tablets, color inspection, shape recognition, counting of tablets, and also for inspection of packaging for recognition of leakage from the packaging of drugs. However, laboratory application segment is expected to grow at a faster rate owing to increasing R&D in this field, and increasing need for reducing human intervention in the process of drug manufacturing.

End use segment comprises of biopharmaceutical companies, and research laboratories. Biopharmaceutical companies to hold the largest share, owing to rising awareness for its use in manufacturing of medicines, and ongoing clinical trials.

The leading companies operating in global Pharmaceutical Robots Market are FANUCA America Corporation, Kawasaki Heavy Industries Ltd., Denso Wave Inc., ABB Ltd., Yaskawa Electric Corporation, Universal Robot A/S, Seiko Epson Corporation, Marchesini Group S.P.A., Kuka AG, and Mitsubishi Electric Corporation.

Read More: https://www.polarismarketresearch.com/industry-analysis/pharmaceutical-robots-market/